Source: Reuters
NEW YORK (Reuters) - Pfizer Inc. said on Tuesday its HIV treatment maraviroc will receive an accelerated review from regulators in the United States and Europe.
If approved by the regulatory agencies, maraviroc would be the first in a new class of HIV/AIDS treatments called CCR5 antagonists that work by blocking viral entry, the drug maker said.
Most existing HIV drugs work inside the body's immune cells, after the virus has infected a patient.
Rather than fighting HIV inside white blood cells, CCR5 antagonists prevent the virus produced by infected cells from entering uninfected cells by blocking its predominant entry route, the CCR5 co-receptor.
The U.S. Food and Drug Administration grants accelerated reviews to potential medicines that could represent a major improvement over current treatments. The expedited process means the agency will decide whether to approve the drug within six months, rather than the more typical period of up to one year.
More information:
Trading Markets.com
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment